MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpainsymman.2026.04.611

Медицинская библиотека · Journal of pain and symptom management · 2026

Intranasal Ketamine for Existential Distress in Advanced Cancer.

Aguiar Stefan, Makarious Mary, Lipsitz Orly, deVries Froukje E, Doyle Zoe, McIntyre Roger S, Rodin Gary, Zimmermann Camilla, Mak Ernie, Hannon Breffni, Schulz-Quach Christian, Al Kindy Aida, Patel Zeal, Rosenblat Joshua D, Li Madeline

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

CONTEXT: Depression and existential distress are highly prevalent among patients with advanced cancer, and there is growing evidence for ketamine as a rapidly acting antidepressant in the population, but few studies have examined existential distress outcomes with ketamine treatment. The INKeD-PC trial demonstrated efficacy of intranasal racemic ketamine for depression in patients with cancer receiving palliative care.

OBJECTIVES

We now report on secondary trial outcomes, including those related to existential distress.

METHODS

This analysis is based on 15 trial participants who received 3 doses of ketamine and completed the primary endpoint measures, including Montgomery-Åsberg Depression Rating Scale as primary outcome, as well as the Patient Health Questionnaire-9 for depression, Generalized Anxiety Disorders-7, Edmonton Symptom Assessment System-Revised, McGill Quality of Life Questionnaire (MQOL), and the Death and Dying Distress Scale. Qualitative comments from participants were used to support quantitative findings.

RESULTS

Improvements were observed across all secondary outcome measures, exceeding established minimal clinically important differences. Were as follows: Generalized Anxiety Disorders-7 (d = 1.22, P= 0.004), Death and Dying Distress Scale (d=0.91, P=0.003), Edmonton Symptom Assessment System-Revised (d = 1.21, P= 0.003) and McGill Quality of Life Questionnaire (d = 1.53, P= 0.004). Correlations between changes in Montgomery-Åsberg Depression Rating Scale and secondary outcomes were not significant, and subscales related to psychological symptoms improved more than physical symptoms, including the MQOL Existential Well-Being factor (d=1.02, P=0.015).

CONCLUSION

Intranasal ketamine was associated with clinically meaningful improvements in existential distress in individuals with advanced cancer being treated for depression. Ketamine may have relevance as a single agent for multidimensional distress in palliative care.

Для цитирования: Aguiar Stefan, Makarious Mary, Lipsitz Orly, deVries Froukje E, Doyle Zoe, McIntyre Roger S, Rodin Gary, Zimmermann Camilla, Mak Ernie, Hannon Breffni, Schulz-Quach Christian, Al Kindy Aida, Patel Zeal, Rosenblat Joshua D, Li Madeline. Intranasal Ketamine for Existential Distress in Advanced Cancer.. Journal of pain and symptom management. 2026. DOI: 10.1016/j.jpainsymman.2026.04.611.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.